Research and projectsResearch groups at IBA MU

Research groups at IBA MU Analysis of Clinical Data

Leader of the research group Leader of the research group: Jiří Jarkovský, Ph.D.

The group of Analysis of Clinical Data at the Institute of Biostatistics and Analyses plays an important role in many clinical research projects.


Leader of the research group:

Jiří Jarkovský, Ph.D.

Jiří Jarkovský, Ph.D.

Contact: jarkovsky@iba.muni.cz

Data analysis is one of the key activities at IBA MU. The portfolio of data analysis covers the whole range of skills required for complete support of clinical and biological projects, from experimental design, through inventive visualisation, descriptive statistics and hypotheses testing, to end-point analysis, predictive modelling, and multivariate data processing.

Data analysis performed by IBA MU teams produces not only summary reports and presentations, but also the interpretation of results and data with knowledge of its biological and clinical background, as well as the preparation of scientific publications for peer-reviewed journals.

Selected projects

Analysis of data from clinical registries

  • Clinical registries represent the main source of clinical data collected at IBA MU. These registries provide a reliable description of clinical practice, focusing on the collection and analysis of data on diagnostic and therapeutic procedures, or monitoring the results of a specific type of treatment. IBA MU runs dozens of clinical registries of the Czech Society of Oncology and of several other medical societies. The principal objectives of these projects involve monitoring and retrospective evaluation of health care in areas where treatment effectiveness and health care improvements are of particular importance. Special attention is paid to modern treatment approaches, innovative medication as well as to projects focused on personalised medicine.
    http://www.registry.cz

Selected publications

  • Büchler T, Bortlíček Z, Poprach A, et al. Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis. Urologic Oncology: Seminars and Original Investigations 2014; 32(5): 569-575. doi: 10.1016/j.urolonc.2013.12.007.
  • Büchler T, Pavlík T, Melichar B, et al. Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis. BMC Cancer 2014; 14: 323. doi: 10.1186/1471-2407-14-323.
  • Chrapek O, Jarkovský J, Šín M, Studnička J, Kolář P, Jirková B, Dušek L, Pitrová Š, Řehák J. Prognostic factors of early morphological response to treatment with ranibizumab in patients with wet age-related macular degeneration. Journal of Ophthalmology, Article ID 867479.
  • Jansa P, Jarkovský J, Al-Hiti H, et al. Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry. BMC Pulmonary Medicine 2014; 14:45. doi: 10.1186/1471-2466-14-45.
  • Kiss I, Bortlíček Z, Melichar B, et al. Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma. Anticancer Research 2014; 34(2): 949-954.
  • Poprach A, Pavlík T, Melichar B, et al. Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines. Urologic Oncology: Seminars and Original Investigations 2014; 32(4): 488-495. doi: 10.1016/j.urolonc.2013.09.011.
  • Salaj P, Kubes R, Cetkovsky P, et al. Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry. Thrombosis Research 2014; 133(2): 162-167. doi: 10.1016/j.thromres.2013.11.002.
  • Slavíček L, Pavlík T, Tomášek J, et al. Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry. BMC Gastroenterology 2014, 14: 53. doi: 10.1186/1471-230X-14-53.
  • Stourac P, Blaha J, Klozova R, Noskova P, Seidlova D, Brozova L, Jarkovsky J. Anesthesia for Cesarean Delivery in the Czech Republic: A 2011 National Survey. Anesthesia & Analgesia 2014 [Epub ahead of print] doi: 10.1213/ANE.0000000000000572.
  • Toušek P, Toušek F, Horák D, et al. The incidence and outcomes of acute coronary syndromes in a central European country: results of the CZECH-2 registry. International Journal of Cardiology 2014; 173(2): 204-208. 10.1016/j.ijcard.2014.02.013.
  • Václavík J, Špinar J, Vindiš D et al. ECG in patients with acute heart failure can predict in-hospital and long-term mortality. Internal and Emergency Medicine 2014, 9(3): 283-291. doi: 10.1007/s11739-012-0862-1.
  • Vyskocilova K, Spinarova L, Spinar J, et al. Prevalence and clinical significance of liver function abnormalities in patients with acute heart failure. Biomedical Papers 2014, doi: 10.5507/bp.2014.014. [Epub ahead of print]
  • Bladen CL, Rafferty K, Straub V, et al. The TREAT-NMD duchenne muscular dystrophy registries: Conception, design, and utilization by industry and academia. Human Mutation 2013; 34(11): 1449-1457. doi: 10.1002/humu.22390.
  • Bladen, CL, Thompson, R, Jackson, JM, et al. Mapping the differences in care for 5,000 Spinal Muscular Atrophy patients, a survey of 24 national registries in North America, Australasia and Europe. Journal of Neurology 2013; 261(1):152-163. doi: 10.1007/s00415-013-7154-1.
  • Fiala O, Pešek M, Fínek J,et al. Erlotinib in the treatment of advanced squamous cell NSCLC. Neoplasma 2013, 60 (6): 676-682. doi: 10.4149/neo_2013_086.
  • Fiala O, Pešek M, Fínek J, et al. Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice. Neoplasma 2013, 60 (1): 26-32. doi: 10.4149/neo_2013_004.
  • Horák P, Skácelová M, Hejduk K, et al. Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic – data from the ATTRA registry. Clinical Rheumatology 2013; 32:1451-1458. doi: 10.1007/s10067-013-2303-6.
  • Hronek M, Kovařík M, Aimová P, et al. Skinfold anthropometry – the accurate method for fat free mass measurement in COPD. COPD 2013; 10(5): 597-603. doi: 10.3109/15412555.2013.781151.
  • Klamová H, Machová Poláková K, Mužík J, et al. Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cut-off levels. Cancer Medicine 2013; 2(2): 216-225. doi: 10.1002/cam4.59.
  • Koblížek V, Chlumský J, Zindr V, et al. Chronic obstructive pulmonary disease: official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care. Biomedical Papers 2013; 157(2): 189-201. doi: 10.5507/bp.2013.039.
  • Pavlík, T, Janoušová, E, Mayer, J, et al. Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications. American Journal of Hematology 2013; 88(9): 790-797. doi: 10.1002/ajh.23508.
  • Studnička J, Říhová B, Rencová E, et al. Cost and effectiveness of therapy for wet age-related macular degeneration in routine clinical practice. Ophthalmologica 2013; 230(1): 34-42. doi: 10.1159/000350802.
  • Büchler T, Klapka R, Melichar B, et al. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry. Annals of Oncology 2012; 23(2): 395–401. doi: 10.1093/annonc/mdr065.
  • Büchler T, Pavlík T, Bortlíček Z, et al. Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma. Medical Oncology 2012; 29(5): 3321-3324. doi: 10.1007/s12032-012-0293-x.
    Joensuu H, Vehtari A, Riihimäki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. The Lancet Oncology 2012; 13(3): 265-274. doi: 10.1016/S1470-2045(11)70299-6.
  • Poprach A, Bortlíček Z, Büchler T, et al. Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database. Medical Oncology 2012; 29(5): 3314-3320. doi: 10.1007/s12032-012-0286-9.
  • Poprach A, Pavlík T, Melichar B, et al. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. Annals of Oncology 2012; 23(12): 3137-3143. doi: 10.1093/annonc/mds145.
  • Rodger S, Antonova V, Brabec P, et al. CARE-NMD: The role of patient registries in an international study of care in Duchenne muscular dystrophy. Neuromuscular Disorders 2012; 22(9): 880. doi: 10.1016/j.nmd.2012.06.255.
  • Salaj P, Ovesna P, Penka M, et al. Analyses of recombinant activated factor VII treatments from clinical practice for rapid bleeding and acute pain control in haemophilia patients with inhibitors. Haemophilia 2012; 18(6): e409-e411. doi: 10.1111/j.1365-2516.2012.02920.x.
  • Salaj P, Penka M, Smejkal P, et al. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: Haemophilia registry data from the Czech Republic. Thrombosis Research 2012; 129(5): e233-e237. doi: 10.1016/j.thromres.2012.02.005.
  • Studnička J, Rencová E, Rozsíval P, et al. Effects of treatment change in patients with neovascular age-related macular degeneration; Results from the Czech National Registry. Biomedical Papers 2012; 156(4): 359-364. doi: 10.5507/bp.2012.100.
  • Vohanka S, Mazanec R, Pavlovska L, et al. ReaDY: The Czech national registry of myotonic disorders. Neuromuscular Disorders 2012; 22(9): 881-882.
  • Vry J, Gramsch K, Rodger S, et al. Current care practice in Duchenne Muscular Dystrophy in Europe - results of the CARE-NMD cross-sectional survey. Neuromuscular Disorders 2012; 22(9): 886-887. doi: 10.1016/j.nmd.2012.06.259.
  • Blatný J, Seidlová D, Penka M, et al. Severe postpartum haemorrhage treated with recombinant activated Factor VII in 80 Czech patients: analysis of the UniSeven registry. International Journal of Obstetric Anesthesia 2011; 20(4): 367-368. doi: 10.1016/j.ijoa.2011.07.008.
  • Faber E, Mužík J, Koza V, et al. Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 – a report from the population-based CAMELIA Registry. European Journal of Haematology 2011; 87(2): 157-168. doi: 10.1111/j.1600-0609.2011.01637.x.
  • Voglová J, Mužík J. Faber E, et al. Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia. Neoplasma 2011; 58(3): 256-262. doi: 10.4149/neo_2011_03_256.
  • Žáčková, D, Klamová, H, Dušek, L, et al. Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials? American Journal of Hematology 2011; 86(3): 318-321. doi: 10.1002/ajh.21942.
  • Zdziarska J, Chojnowski K, Klukowska A, et al. Registry of inherited bleeding disorders in Poland - current status and potential role of the HemoRec database. Haemophilia 2011; 17(1): e189-e195. doi: 10.1111/j.1365-2516.2010.02371.x.
  • Brabec P, Šufliarsky J, Linke Z, et al. A whole population study of gastrointestinal stromal tumors in the Czech Republic and Slovakia. Neoplasma 2009; 56(5): 459-464. doi: 10.4149/neo_2009_05_459.
  • Brabec P, Vondráček P, Klimeš D, et al. Characterization of the DMD/BMD patient population in Czech Republic and Slovakia using an innovative registry approach. Neuromuscular Disorders 2009; 19(4): 250-254. doi: 10.1016/j.nmd.2009.01.005.
  • Holzerová M, Faber E, Veselovská J, et al. Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results. Cancer Genetics and Cytogenetics 2009; 191(1): 1-9. doi: 10.1016/j.cancergencyto.2008.12.013.
  • Puetz J, Darling G, Brabec P, et al. Thrombotic events in neonates receiving recombinant factor VIIa or fresh frozen plasma. Pediatric Blood & Cancer 2009; 53(6): 1074-1078. doi: 10.1002/pbc.22160.
  • Salaj P, Brabec P, Penka M, et al. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic. Haemophilia 2009; 15(3): 752-759. doi: 10.1111/j.1365-2516.2009.02007.x.
  • Smejkal P, Brabec P, Matyskova M, et al. FEIBA((R)) in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: a retrospective survey in regional haemophilia centre. Haemophilia 2009; 15(3): 743-751. doi: 10.1111/j.1365-2516.2009.02012.x.

 


Back